Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Clinical trial NCT06149481 · RECRUITING
Trial details
- NCT number
- NCT06149481
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-26
- Primary completion
- 2027-10-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.